Press Releases InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects January 8, 2021 Read More » InMed to Participate at Virtual Conferences in January 2021 January 5, 2021 Read More » InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More » InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More » InMed Announces Election of Directors November 25, 2020 Read More » InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More » InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More » InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results November 13, 2020 Read More » InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM” November 12, 2020 Read More » InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020 November 5, 2020 Read More » InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020 November 4, 2020 Read More » InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects September 24, 2020 Read More » InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing September 22, 2020 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More » InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More » InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755 July 7, 2020 Read More » InMed Announces Completion of Share Consolidation June 30, 2020 Read More » InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More » InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More » InMed Releases CBN Preclinical Results in Glaucoma May 27, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects January 8, 2021 Read More »
InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids December 3, 2020 Read More »
InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects November 25, 2020 Read More »
InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics November 18, 2020 Read More »
InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering November 16, 2020 Read More »
InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results November 13, 2020 Read More »
InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol “INM” November 12, 2020 Read More »
InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020 November 5, 2020 Read More »
InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020 November 4, 2020 Read More »
InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects September 24, 2020 Read More »
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More »
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More »
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More »
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More »
